Immunomedics (IMMU) Misses Q2 EPS by 50c

Immunomedics (NASDAQ: IMMU) reported Q2 EPS of ($0.84), $0.50 worse than the analyst estimate of ($0.34).

As of December 31, 2018, the Company had $497.8 million in cash, cash equivalents, and marketable securities, which it believes is adequate to support its clinical development plan for sacituzumab govitecan; further build its clinical and manufacturing infrastructure and fund its operations through 2020.

For earnings history and earnings-related data on Immunomedics (IMMU) click here.

You May Also Be Interested In

• Broadcom credit risk measures rise amid AI financing deals
• Bernstein SocGen on StandardAero Inc (SARO): ' Solid revenues, but short-term margin issues'
• X Financial (XYF) Tops Q2 EPS by 438c